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combine probability data estimated from published liter-
ature and Polish data on resource use and unit cost.
Target population was people aged 70.58% women. The
perspective of Health care payer’s was adopted and only
direct medical costs were analysed. The outcome mea-
sures were life years gained (LYG), calculated on the basis
of available evidence for a preventive effect of enoxaparin
on VTE risk after elective hip replacement. Incremental
cost-effectiveness ratio was calculated to provide esti-
mates of the cost per life year gained. The cost-
effectiveness threshold was calculated on the basis of 
1-year haemodialysis treatment cost (60,000 PLN, €1 =
4 PLN; in 2003). The one-way and scenario sensitivity
analyses were performed. RESULTS: For hypothetical
cohort of 100 patient undergoing elective hip replacement
the expected cost and outcome were 53,470 PLN and
1269.4 LY for extended and 33,190 PLN and 1248.2 LY
for standard enoxaparin as prophylaxis for VTE. For 
the extended enoxaparin group this translated to 952
PLN/LYG. A series of one-way and scenario analyses
showed modest change in cost/LYG. In no instance did
the ICER exceed 3000 PLN/LYG. CONCLUSION:
Prolonged enoxaparin prophylaxis after elective hip
replacement is more effective than conventional short-
term prophylaxis in terms of LYG and also appears to be
clearly cost-effective, using Polish cost data.
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OBJECTIVES: To analyze and compare medium and
long-term clinical and economic outcomes of fonda-
parinux and enoxaparin in the prevention of venous
thromboembolism (VTE) after major orthopaedic surgery
(MOS) in Spain. METHODS: A decision-analytic model
was adapted to determine the incidence and cost conse-
quences of VTE-related events (deep vein thrombosis—
DVT, pulmonar embolism—PE, and post-thrombotic
syndrome—PTS) and major bleedings due to their pro-
phylaxis and treatment, in 2 hypothetic cohorts of 10,000
MOS patients each who had received either 8 injections
of enoxaparin or 7 injections of fondaparinux. Clinical
outcomes and their direct cost consequences for the
National Health System were calculated for different time
horizons (1 month, 3 months, 1 year, and 5 years after
surgery). Clinical input data were retrieved from pub-
lished clinical trials and epidemiological studies. Resource
use in the prophylaxis and management of all events was
determined by an international expert panel using the
Delphi technique and was validated for Spain by a local
VTE expert. Unit costs of the resources were extracted
from local databases and were expressed in Euros of
2002. Costs were discounted at 3% per year. RESULTS:
Five years after surgery mortality caused by PE was 46%
less in the fondaparinux cohort, while mortality due to
major bleedings following prophylaxis or treatment of
VTE did not differ between cohorts. The accumulated
number of cases of DVT, PE, and PTS were, respectively,
33%, 46%, and 26% less. Additional drug cost with 
fondaparinux amounted to €14,582 per life saved. 
From three months after surgery onwards the price 
differential was compensated by savings that resulted 
from the avoidance of VTE-related events. CONCLU-
SIONS: Prophylaxis with fondaparinux vs. enoxaparin
considerably reduces the number of fatalities and other
VTE-related events after MOS and leads to net savings
for the National Health System in the medium and long
term.
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OBJECTIVES: The CURE study has demonstrated that
clopidogrel on top of standard therapy (including aspirin,
ASA) decreases the risk of cardiovascular death, myocar-
dial infarction and stroke by 20% in patients with acute
coronary syndromes without ST- elevation. The objective
of this study was to evaluate the cost-effectiveness of
adding clopidogrel to standard treatment in the Nether-
lands. METHODS: The cost-effectiveness, in terms of
costs per saved life-year, was determined with a Markov
model in which patients were divided according to vas-
cular events and time from last event. Effectiveness data
were derived from the CURE study; long-term outcomes
were based on epidemiological estimates concerning age
speciﬁc event rates and case fatality rates. Quality of life
estimates were obtained from the literature. Direct costs
were updated from previous studies, indirect costs were
disregarded due to the age of the patients. RESULTS: The
number needed to treat with clopidogrel for one year to
prevent one event was 35. The annual cost of treatment
was €20.355 in patients treated with clopidogrel on top
of standard therapy (including ASA) and €20.342 in
patients in the control group (standard therapy including
ASA). After discounting costs and effects at 4%, treat-
ment with clopidogrel resulted in annual cost saving of
€17 per patient. There was also a gain in life-years and
quality adjusted life years (QUALY’s) of 0.122 year and
0.137 QALY’s per patient. Multivariate sensitivity analy-
ses revealed that the results are robust. CONCLUSIONS:
Clopidogrel is highly cost-effective when added to stan-
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dard treatment, including ASA, in patients with acute
coronary syndromes without ST-elevation.
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OBJECTIVES: To analyse the efﬁciency of the use of a
percutaneous transluminal coronary angioplasty (PTCA),
a coronary artery bypass graft (CABG), a conventional
Stent or a sirolimus-eluting Stent (Cypher) in the treat-
ment of Ischaemic Heart Disease (IHD) by means of a
cost-effectiveness analysis. METHODS: An international
decision analytical model was adapted to the Spanish
National Health System perspective in a time horizon of
1 year for 4 different populations of general patients with
IHD according to the type of vessel or lesion (one or 
multiple, small vessel—less that 3mm diameter, or long
lesion—more than 18mm long). The primary outcome of
the model was the cost per revascularisation avoided with
each technique when compared to a conventional Stent
(in the multiple lesions model the PTCA has not been 
considered as a relevant option). Incidence rates of re-
vacularisation for each subgroup were obtained from
published clinical trials and epidemiological studies.
Resource use data was determined by an expert panel.
Unit costs of the resources were extracted from local data-
bases and were expressed in Euros of 2002. RESULTS:
The PTCA has the lowest efﬁcacy with revascularisation
rates ranging from 19% to 28%) whilst the sirolimus
eluting-Stent is the most efﬁcacious option (rates ranging
from 1% to 4%. The less costly option is PTCA and the
most expensive in all types of patients is the CABG. Cost
per revascularisation avoided ranges between €1,042 of a
PTCA in small vessel patients to €56,035 with CABG in
patients with lesions in normal vessels. Cypher is a cost-
effective option in patients with normal vessels and long
lesions and becomes dominant in the multiple lesions
model. CONCLUSIONS: Drug eluting Stents have
proven efﬁcacy rates that have no precedents in the
history of IHD, reducing the incidence of revascularisa-
tion induced by restenosis and thus resulting in efﬁcient
options in most types of patients.
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OBJECTIVES: To quantify the economic value of the
sirolimus-eluting stent (SES) in treating acute coronary
heart disease, and to assist in determining its adequate
reimbursement price under the mandatory national health
insurance system in Korea. METHODS: A decision-
analytic model was used to investigate the incremental
cost-effectiveness of SES versus conventional stenting
(CS). Probabilities for clinical events were obtained from
the results of large, randomized, controlled clinical trials.
Types of costs included in the analysis were initial proce-
dure and hospitalization costs, and follow-up direct
medical costs for 5 years consisting of routine follow-up
treatments, adverse reactions, revascularization and death
costs. Cost information was obtained from administrative
data for 449 patients receiving CS in June 2002 from 5
Korean hospitals participating in this study. Since the
major clinical advantage of SES over CS is the reduction
of revascularization rates, we evaluated economic value
of SES in relation to direct medical costs of revascular-
ization. According to the customary notion in Korea, the
reimbursement price was deﬁned as the price of SES that
made the incremental cost-effectiveness ratio equal to the
cost of a revascularization itself. RESULTS: The esti-
mated reimbursement price for SES was US$3344 using
a discount rate of 5%. Based on this price, the national
ﬁnancial impact of replacing CS with SES by 10% was
estimated as extra spending of $0.96 million a year, 0.6%
increase in total national spending in treating coronary
artery disease in Korea. CONCLUSIONS: Analysis on 
the economic value of SES based on Korean cost struc-
ture of coronary artery disease provided objective stan-
dard for pricing decision and reimbursement strategy in
Korea.
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OBJECTIVE: A recently published analysis on the use 
of Cholesterol-Synthesis-Enzyme-Antagonists (CSEA) in
Germany stated that with the investment of nearly €1
billion; 87% of all possible €2.8 million. patients can be
treated sufﬁciently (Klose and Schwabe 2003). The aim
of the presented study is to show the cost-efﬁcacy as expe-
rienced by ofﬁce based physicians of the CSEA treatment.
METHODS: A cost-efﬁcacy-analysis was conducted on
base of the following data: Eight local experts (general
practitioners, cardiologists) out of a rural as well as an
urban setting assessed in a Delphi-Panel their practical
experience of reaching a deﬁned LDL-Cholesterol (LDL-
C) target according to European treatment guidelines
treating a patient with a predeﬁned risk with CSEA. Total
sales of CSEA in 2002 as stated by IMS (Institute for
